Trilobio Raises $8M to Deliver Whole Lab Automation for Biologists
Trilobio was founded in 2021 to address the established data quality and reproducibility challenges limiting research efficiency; it is estimated that 77% of biologists cannot reproduce their own or other's research, despite latest advances in laboratory automation tools (1). Trilobio's co-founders, Roya Amini-Naieni and Maximilian Schommer, were named on Forbes' 30 Under 30 list for their contributions to advances in Manufacturing & Industry. To date, the Company has raised over $11 million, including support from Julian Capital, Juniper, Future Labs Capital, 1517 Fund, Alumni Ventures, Angel Squad, Sequel, Nucleus Capital, Gaingels and others, and has deployed its whole laboratory automation platform at leading biology labs across the United States.
This investment will support the expansion of the Trilobio Platform's robotics capabilities and no-code software features, enabling a growing portfolio of purpose-built lab devices and protocols to be integrated into a single, fully automated platform. Leveraging continual advancement and expansion of the Platform, Trilobio is providing an accessible and scalable solution to transform genetic engineering, synthetic biology and life science research processes, enabling scientists at the cutting-edge to execute research reproducibly, rapidly, and accurately.
Roya Amini-Naieni, CEO and Co-Founder at Trilobio, commented: 'Today's research is more collaborative, innovative, and insightful than ever before, and yet has not reached its full potential because of our inability to reliably reproduce, share, and collectively improve experiments. The future of the field depends on affordable new technologies that empower scientists to overcome these obstacles. '
She added: 'Our mission at Trilobio is to redefine the relationship between scientists and the technologies that power their work every single day, enabling new scientific heights to be reached. We are thankful to have the support of a fantastic portfolio of investors who share our vision. It's time for true automation–connecting and fully automating all processes in the modern biology lab and making the dream of walk-away capabilities a reality.'
The Trilobio Platform consists of the foundational robot, the Trilobot, which is fully programmable through Trilobio OS, the intelligent no-code protocol design software. Each Trilobot houses up to eight different interchangeable lab device tools, effectively creating a self-contained lab in a single device, for example grippers, various pipette tools, and a tube cap/de-capper. The Trilobots, which automatically calibrate themselves and plasticware, can be instantly linked together and work collaboratively, enabling a fleet to be adjusted to individual research requirements and scale capacity instantly.
A user's research protocol is entered into Trilobio OS just like writing a lab notebook entry, initiating the software engine to plan and execute all details without further action required and eliminating hours of coding and research design. Trilobio OS determines the optimal execution of the protocol which can be automatically adjusted for speed, cost, or accuracy. In total, the Trilobio Platform is purpose-built to ensure each step of the workflow is reproducible in any other Trilobio-enabled lab, without the need for hardware recalibration or rewrite of protocols. By providing a reliable and standardized approach, the technology streamlines research design and execution time down to minutes from days or even weeks.
'Roya and Max are uniquely qualified to build the future of lab automation given their interdisciplinary expertise in biology and robotics. I've never seen another founding team with this skillset," said Andrew Sather, Partner at Initialized Capital. "Trilobio is a force-multiplier for the Bio Age, empowering scientists to improve our quality of life and move our species forward."
For more information about Trilobio's platform, please visit: https://trilo.bio/.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
UnitedHealth Group Announces Changes to Leadership Team
July 31, 2025--(BUSINESS WIRE)--UnitedHealth Group (NYSE: UNH) today announced Wayne S. DeVeydt has been appointed its chief financial officer, effective September 2, 2025. John F. Rex, who joined the company in 2012 and has been CFO since 2016, will become strategic advisor to the CEO on the same date. "Wayne DeVeydt combines deep financial acumen and operating experience with the mission-oriented and compassionate approach to health care that is a perfect fit for UnitedHealth Group," said Stephen J. Hemsley, company chairman and chief executive officer. "John Rex has been an exceptional leader, having helped guide our company through substantial change with both strategic vision and strong commitment to our mission," said Hemsley. "I look forward to his continued insights as UnitedHealth Group moves forward." DeVeydt, 55, most recently has been a managing director and operating partner at Bain Capital, working with client leaders on operational improvement and growth acceleration. From 2018-2020, he was chairman and CEO of Surgery Partners, Inc. in Nashville, expanding the operational scale and financial performance of the surgical services firm. He joined Anthem, Inc. (now Elevance) in 2005 and served as its chief financial officer from 2007 to 2016. Prior to joining Anthem, DeVeydt served as a partner with PricewaterhouseCoopers LLP, with a focus on the health care sector. "There is no organization besides UnitedHealth Group that presents the kinds of opportunities to make a difference in health care, from individual patient care to broad system efficiency, so I am eagerly looking forward to joining the team," said DeVeydt. "I've been fortunate to know John Rex for over two decades and am honored to follow a leader of his caliber." Rex, 63, joined UnitedHealth Group as chief financial officer of the company's then newly established Optum business and previously had spent his career focused in health care across multiple roles and sectors. "This pivotal moment for UnitedHealth Group is the right time for a new yet greatly experienced executive like Wayne DeVeydt, and I look forward to supporting him and the entire leadership team while continuing to advise on a range of matters," said Rex. About UnitedHealth Group UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at and follow UnitedHealth Group on LinkedIn. View source version on Contacts Media: uhgmedia@ UnitedHealth Group Media Sign in to access your portfolio
Yahoo
6 hours ago
- Yahoo
Cleveland-Cliffs (CLF) Reports Q2 2025 Sales Decline to US$4934 Million
Cleveland-Cliffs recently faced challenges as their second-quarter 2025 earnings revealed sales declined to USD 4,934 million, while registering a net loss of USD 483 million compared to a modest net income last year. Despite these disappointing financial results, Cleveland-Cliffs's share price rose by 15% over the past month. This performance unfolded against the backdrop of a broader market that saw similar gains in July, although markets experienced a downturn due to economic concerns fueled by weak U.S. jobs data and renewed tariff policies. The company's operational struggles might have tempered the overall positive market momentum. We've identified 3 risks with Cleveland-Cliffs (at least 1 which is a bit unpleasant) and understanding the impact should be part of your investment process. Find companies with promising cash flow potential yet trading below their fair value. The recent earnings report highlighting Cleveland-Cliffs' net loss of US$483 million amidst sales of US$4.93 billion presents a challenging landscape for the company. Despite this, shares have climbed 15% in the past month, reflecting broader market trends, though these gains might be vulnerable to ongoing economic uncertainties, such as the U.S. jobs data concerns. Addressing this financial strain is crucial as Cleveland-Cliffs navigates its reliance on U.S. steel tariffs and OEM reshoring, central to its growth narrative. Over a longer five-year period, Cleveland-Cliffs' total shareholder return, encompassing both share price appreciation and dividends, marked an impressive increase of 83.58%. This growth sharply contrasts with the company's recent underperformance against the US Metals and Mining industry over the past year. The industry saw returns of 13.4%, surpassing Cleveland-Cliffs' performance during the same one-year period. Future revenue and earnings projections are aligned with anticipated benefits from reshoring and tariff protections, yet the magnitude of the recent loss highlights potential vulnerabilities. Analysts anticipate the revenue will rise, with margins eventually reaching profitability. However, any shifts in trade policies or market conditions could alter these forecasts. With the current share price at US$10.06, close to the target of US$10.99, the upward movement suggests market confidence, yet analysts see limited upside relative to the target, indicating cautious optimism about hitting expected milestones. According our valuation report, there's an indication that Cleveland-Cliffs' share price might be on the cheaper side. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CLF. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 hours ago
- Yahoo
BNB Slides as Tariffs, Stronger Dollar and Fed Policy Weigh on Crypto Markets
BNB fell more than 4.5% in the last 24 hours, dropping from around $805.7 to $766 at the time of writing as investors move away from risk assets as U.S. interest-rate cut hopes faded. The selling accelerated near $803, where a surge in trading volume, roughly 56% above average, marked a turning point, according to CoinDesk Research's technical analysis model. BNB sank sharply from there, slicing through short-term support zones near $789 and $777. Overnight, the $767 level emerged as a key battleground, absorbing heavy sell orders and stalling the decline. Despite a small bounce toward $769, buying momentum faded quickly. The drop comes as President Donald Trump's tariffs start to take effect, with some kicking in today and others on Aug. 7. These tariffs saw the U.S. dollar index rise above 100 for the first time since May. Adding to the stronger dollar, interest rates may remain higher for longer. The Federal Reserve's preferred inflation measure, the core PCE, rose 2.8% year-over-year in June, damping hopes for a rate cut in September. The BNB slide mirrors the larger crypto landscape, with the CoinDesk 20 (CD20) index dropping 5.8% in the past 24 hours. The cryptocurrency is nevertheless seeing growing corporate adoption. CEA Industries (VAPE), backed by Binance co-founder Changpeng Zhao's family office, Yzi Labs, announced plans to raise up to $1.2 billion to build what it called the largest U.S.-listed BNB treasury. They aren't alone. Liminatus Pharma (LIMN), a clinical-stage biopharma firm, launched a BNB investment arm with a $500 million funding goal. Windtree Therapeutics (WINT) disclosed a $700 million BNB acquisition strategy, while Nano Labs reported buying 128,000 BNB as part of its new crypto treasury plan. Disclaimer: Parts of this article were generated with the assistance from AI tools and reviewed by our editorial team to ensure accuracy and adherence to our standards. For more information, see CoinDesk's full AI Policy.
